Further, a combination therapy, comprising i) “therapeutic” T cells with ii) antibodies targeting classical ICIs such as α-PD-1 and/or cancer vaccines based e.g. on attenuated Listeria monocytogenes as recently developed in our study (66), could be further considered, especially at advanced stages of this highly aggressive malignant liver disease. The gene discussed is PDCD1; the disease is cancer.